UBS Upgrades Lifestance Health Stock Target to $9 with Maintained Neutral Rating

Thursday, 29 February 2024, 13:14

UBS has increased the stock target for Lifestance Health to $9 while keeping the rating at neutral. The strategic move indicates positive sentiment towards the performance of Lifestance Health in the market with a steady approach.

LivaRava Finance Meta Image — UBS Upgrades Lifestance Health Stock Target to $9 with Maintained Neutral Rating

UBS Upgrades Lifestance Health Stock Target to $9 with Neutral Rating

UBS has raised the stock target for Lifestance Health to $9 while maintaining a neutral rating for the company.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.